Navigation Links
Infants going to day-care may have lower risk of leukemia

British scientists have found that increased exposure to infections in early infancy, as staying in a day-care //center, may reduce the risk of developing acute lymphoblastic leukemia.

The study results were compiled from 6305 children across ten regions of UK of age 2 to 14 yrs without cancer and 3140 children with cancer, of whom 1286 had acute lymphoblastic leukemia. Day care and social activities were taken as places were children could be most exposed to infections.

Acute lymphoblastic leukemia (ALL) is a form of cancer that affects the lymphocyte producing cells. These cells stay in the bone marrow. Lymphocytes are white blood cells are the most important ingredient of the body’s immunity. In ALL, there is an accumulation of lymphocyte precursor cells, also called blast cells, in the bone marrow.

The results of the study showed that increased social activities could be related to lower risk of acute lymphoblastic leukemia. On one hand, the children with cancer and those who were healthy were found to have similar risk from infections, with or without being in day-care. However, when children with other forms of cancer were related to those suffering from ALL, formal day-care center seems to act as a protective factor against onset of ALL.
'"/>




Page: 1

Related medicine news :

1. Banning Smoking in the Home Helps Infants
2. Benefits of Nitric Oxide in the Treatment of Premature Infants
3. New Technique to Study Infants Brain.
4. Limiting Infants Exposure To Smoke At Home
5. fMRI Offers Insight Into An Infants Brain
6. Drug Used To Improve Lung Function In Infants Could Slow Down Motor Coordination
7. Infants at lower risk from digestive disease if introduced to cereal early
8. New Blood Test To Detect Iron Level In Infants
9. Infants must be put to sleep in separate beds to prevent SIDS
10. Plump Infants Getting Obese Later In Life In More Cases
11. Effect of Maternal Diet on Colic Among Breastfed Infants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: